Vericiguat
Vericiguat, sold as Verquvo, is a soluble guanylate cyclase stimulator, a medicine taken by mouth. The US label read lists one use in adults: to reduce the risk of cardiovascular death and hospitalization for heart failure after a hospitalization for heart failure or the need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction below 45%. The label carries a boxed warning for embryo-fetal toxicity, which concerns the unborn child and is recorded separately.
Also called Verquvo
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 2475830; UNII LV66ADM269. MeSH has no descriptor for vericiguat (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Soluble Guanylate Cyclase Stimulator. The record is filed under the class page for soluble guanylate cyclase stimulators on that evidence. The label read is the Merck Sharp & Dohme LLC label for Verquvo, application NDA214377, effective 2026-01-21 in openFDA. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the title and one sentence of the boxed warning, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says vericiguat stimulates soluble guanylate cyclase, an enzyme in the nitric oxide signaling pathway.
Claims and evidence
Context Adults with symptomatic chronic heart failure and an ejection fraction below 45%, as described in the US label of Verquvo
- Recipient
- Adult
- Population
- Adults with symptomatic chronic heart failure and an ejection fraction less than 45%, following a hospitalization for heart failure or the need for outpatient intravenous diuretics, as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adults with symptomatic chronic heart failure and ejection fraction less than 45%
- Following a hospitalization for heart failure or need for outpatient intravenous diuretics
- Excluded
- None stated
The US label of Verquvo (vericiguat tablets, Merck Sharp & Dohme LLC, application NDA214377; the version dated 2026-01-21 in openFDA) describes vericiguat as a soluble guanylate cyclase stimulator. It lists reducing the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.
Applies to Adult Adults with symptomatic chronic heart failure and an ejection fraction below 45%, as described in the US label of Verquvo
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The boxed warning is in a separate claim about the fetus. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, second sentence
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-05, LB-06).
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260121.
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context The developing fetus, for a person taking vericiguat during pregnancy, as described in a US label boxed warning
- Recipient
- Fetal
- Population
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Pregnancy during which the medicine is taken (risk to the fetus)
- Excluded
- None stated
The same US label of Verquvo carries a boxed warning titled embryo-fetal toxicity. It says the medicine may cause fetal harm.
Applies to Fetal The developing fetus, for a person taking vericiguat during pregnancy, as described in a US label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first paragraph
- How it applies
- Label passage quoted in the research quote table (LB-08).
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260121.
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In pregnancy 1
The same US label of Verquvo carries a boxed warning titled embryo-fetal toxicity. It says the medicine may cause fetal harm.
Applies to Fetal The developing fetus, for a person taking vericiguat during pregnancy, as described in a US label boxed warning
Population, setting and follow-up
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first paragraph
- How it applies
- Label passage quoted in the research quote table (LB-08).
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260121.
- Retrieved
- Source effective date
- 2026-01-21
- Source state
- Current
- Version fingerprint
efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and an ejection fraction less than 45% as an indication: Heart failure
Applies to Adult Adults with symptomatic chronic heart failure and an ejection fraction below 45%, as described in the US label of Verquvo
The US label of Verquvo (vericiguat tablets, Merck Sharp & Dohme LLC, application NDA214377; the version dated 2026-01-21 in openFDA) describes vericiguat as a soluble guanylate cyclase stimulator. It lists reducing the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The boxed warning is in a separate claim about the fetus. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:vericiguat- Content hash
c94c5f6dba6a2a04cc230cfb0dc7e3800a84311a848d2060d0b3f04fbf69fab8